BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of…
- The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consistently favored acoramidis treatment…